Online inquiry

IVTScrip™ mRNA-Anti-IL6R, BCD-089(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3861MR)

This product GTTS-WQ3861MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets IL6R gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_000565.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3570
UniProt ID P08887
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL6R, BCD-089(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ3861MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ836MR IVTScrip™ mRNA-Anti-CD276, ABBV-155(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABBV-155
GTTS-WQ9520MR IVTScrip™ mRNA-Anti-FOLH1, J-591(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA J-591
GTTS-WQ2787MR IVTScrip™ mRNA-Anti-IL1RL1, AMG-282(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG-282
GTTS-WQ13463MR IVTScrip™ mRNA-Anti-ERBB2&TNFRSF9, PRS-343(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA PRS-343
GTTS-WQ3325MR IVTScrip™ mRNA-Anti-VEGFA, AT-001(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AT-001
GTTS-WQ13122MR IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PF-04360365
GTTS-WQ4898MR IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BYM338
GTTS-WQ3006MR IVTScrip™ mRNA-Anti-KDR, Angiocept(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA Angiocept
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW